Control Bionics Ltd. (ASX:CBL) Financings

Control Bionics Ltd.

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares
Announced: about A$9.5M · A$0.075 a share · Bell Potter Securities Limited +1
Dealers: Bell Potter Securities Limited (co-lead), Unified Capital Partners Pty Ltd (co-lead)
Buyers: Stephen Rix (2,040,000 shares, subject to shareholder approval); Jeremy Steele (1,160,000 shares, subject to shareholder approval); Nicholas Opie (400,000 shares, subject to shareholder approval); Robert Heard (333,333 shares, subject to shareholder approval); Damian Lismore (320,000 shares, subject to shareholder approval)
Insiders: Tranche 2 includes approximately 4.3 million shares (4,253,333) to directors, subject to shareholder approval
Use of proceeds: Commercialisation initiatives and working capital
Jun 25, 2026US$6.57M
Share purchase plan of new shares
Announced: up to A$500,000 · A$0.075 a share
Use of proceeds: Commercial expansion, platform and medtech development, strategic initiatives, working capital and offer costs
Jun 25, 2026US$345,572
Private placement of new fully paid ordinary shares
Announced: A$3.25M · A$0.065 a share
Buyers: Reitham Equity GmbH (anchored the placement)
Use of proceeds: Working capital to accelerate commercialisation of core assistive technology products and emerging neurotechnology markets
Dec 1, 2025US$2.13M

Read by 6ix AI from the company's releases